Xiaojuan Yan1, Michael Fraser, Qing Qiu, Benjamin K Tsang. 1. Reproductive Biology Unit and Division of Gynecologic Oncology, Department of Obstetrics and Gynaecology, University of Ottawa, Ottawa Health Research Institute, 725 Parkdale Avenue, Ottawa, Ontario, Canada, K1Y 4E9.
Abstract
OBJECTIVE: Resistance to cisplatin-centered chemotherapy is a major cause of treatment failure in human ovarian cancer. Whereas PTEN, a tumor suppressor gene product, is believed to promote apoptosis primarily via inactivation of the PI3K/Akt cell survival pathway, recent evidence suggests that PTEN may function independently of this pathway. Activation of p53 is a key determinant of sensitivity to cisplatin-induced apoptosis. Whether PTEN can facilitate cisplatin sensitivity, and this involves the activation of p53, remains unclear. In this study, we determined whether and how PTEN over-expression sensitizes ovarian cancer cells to CDDP-induced apoptosis. METHODS AND RESULTS: Using pairs of chemosensitive and chemoresistant ovarian cancer cell lines (OV20028 vs. C13* and A2780-s vs. A2780-cp) as an in vitro model, we have examined the influence of PTEN over-expression in regulation of cisplatin-induced apoptosis. Apoptosis was assessed morphologically by Hoechst staining and confirmed by the detection of cleaved products of caspase-3 and PARP by Western blot. Over-expression of PTEN by PTEN cDNA transfection up-regulates p53 content and increases the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phosphorylated Akt and FKHR as well as FasL mRNA abundance as determined by Western blot and RT-PCR, respectively. PTEN-mediated chemosensitization was attenuated by p53 down-regulation by siRNA in C13*, a chemoresistant wild-type p53 cell. Moreover, PTEN over-expression failed to sensitize the chemoresistant p53 mutant ovarian cancer cell line A2780-cp to cisplatin-induced apoptosis, unless wild-type p53 was reconstituted by adenoviral p53 infection. CONCLUSION: Taken together, these data suggest that PTEN over-expression may represent a novel therapeutic approach for chemoresistant human ovarian cancer and that this may involve a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway.
OBJECTIVE: Resistance to cisplatin-centered chemotherapy is a major cause of treatment failure in humanovarian cancer. Whereas PTEN, a tumor suppressor gene product, is believed to promote apoptosis primarily via inactivation of the PI3K/Akt cell survival pathway, recent evidence suggests that PTEN may function independently of this pathway. Activation of p53 is a key determinant of sensitivity to cisplatin-induced apoptosis. Whether PTEN can facilitate cisplatin sensitivity, and this involves the activation of p53, remains unclear. In this study, we determined whether and how PTEN over-expression sensitizes ovarian cancer cells to CDDP-induced apoptosis. METHODS AND RESULTS: Using pairs of chemosensitive and chemoresistant ovarian cancer cell lines (OV20028 vs. C13* and A2780-s vs. A2780-cp) as an in vitro model, we have examined the influence of PTEN over-expression in regulation of cisplatin-induced apoptosis. Apoptosis was assessed morphologically by Hoechst staining and confirmed by the detection of cleaved products of caspase-3 and PARP by Western blot. Over-expression of PTEN by PTEN cDNA transfection up-regulates p53 content and increases the sensitivity of chemoresistant cells to cisplatin-induced apoptosis without detectable changes in the levels of phosphorylated Akt and FKHR as well as FasL mRNA abundance as determined by Western blot and RT-PCR, respectively. PTEN-mediated chemosensitization was attenuated by p53 down-regulation by siRNA in C13*, a chemoresistant wild-type p53 cell. Moreover, PTEN over-expression failed to sensitize the chemoresistant p53 mutant ovarian cancer cell line A2780-cp to cisplatin-induced apoptosis, unless wild-type p53 was reconstituted by adenoviral p53infection. CONCLUSION: Taken together, these data suggest that PTEN over-expression may represent a novel therapeutic approach for chemoresistant humanovarian cancer and that this may involve a p53-mediated apoptotic cascade independent of the PI3K/Akt pathway.
Authors: Marina Gálvez-Peralta; Karen S Flatten; David A Loegering; Kevin L Peterson; Paula A Schneider; Charles Erlichman; Scott H Kaufmann Journal: Mol Pharmacol Date: 2014-02-25 Impact factor: 4.436
Authors: Christopher Breed; Douglas A Hicks; Patricia G Webb; Carly E Galimanis; Benjamin G Bitler; Kian Behbakht; Heidi K Baumgartner Journal: Mol Cancer Res Date: 2019-01-03 Impact factor: 5.852
Authors: Tan Min Chin; Margaret P Quinlan; Anurag Singh; Lecia V Sequist; Thomas J Lynch; Daniel A Haber; Sreenath V Sharma; Jeffrey Settleman Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: Dolores Hambardzumyan; Oren J Becher; Marc K Rosenblum; Pier Paolo Pandolfi; Katia Manova-Todorova; Eric C Holland Journal: Genes Dev Date: 2008-02-15 Impact factor: 11.361
Authors: Ximeng Liu; Katia J Bruxvoort; Cassandra R Zylstra; Jiarong Liu; Rachel Cichowski; Marie-Claude Faugere; Mary L Bouxsein; Chao Wan; Bart O Williams; Thomas L Clemens Journal: Proc Natl Acad Sci U S A Date: 2007-02-07 Impact factor: 11.205